Share on StockTwits
 

West Pharmaceutical Services (NYSE:WST) was upgraded by equities researchers at Ned Davis Research from a “neutral” rating to a “buy” rating in a research report issued on Monday, AnalystRatingsNetwork reports.

Separately, analysts at Jefferies Group raised their price target on shares of West Pharmaceutical Services from $36.50 to $45.00 in a research note to investors on Monday, November 4th. They now have a “hold” rating on the stock.

West Pharmaceutical Services (NYSE:WST) traded up 0.42% during mid-day trading on Monday, hitting $49.9006. The stock had a trading volume of 128,019 shares. West Pharmaceutical Services has a 1-year low of $27.305 and a 1-year high of $50.66. The stock’s 50-day moving average is $48.95 and its 200-day moving average is $42.59. The company has a market cap of $3.485 billion and a P/E ratio of 32.02.

West Pharmaceutical Services (NYSE:WST) last issued its quarterly earnings data on Thursday, October 31st. The company reported $0.39 earnings per share for the quarter, beating the analysts’ consensus estimate of $0.36 by $0.03. The company had revenue of $341.80 million for the quarter, compared to the consensus estimate of $333.25 million. During the same quarter in the previous year, the company posted $0.52 earnings per share. The company’s revenue for the quarter was up 12.5% on a year-over-year basis. Analysts expect that West Pharmaceutical Services will post $1.62 EPS for the current fiscal year.

The company also recently announced a quarterly dividend, which is scheduled for Wednesday, February 5th. Shareholders of record on Wednesday, January 22nd will be paid a dividend of 0.10 per share. This represents a $0.40 annualized dividend and a dividend yield of 0.80%. The ex-dividend date is Friday, January 17th.

West Pharmaceutical Services, Inc (NYSE:WST) is a manufacturer of components and systems for the packaging and delivery of injectable drugs, as well as delivery system components for the pharmaceutical, healthcare and consumer products industries.

Get Analysts' Upgrades and Downgrades via Email - Stay on top of analysts' coverage with Analyst Ratings Network's FREE daily email newsletter that provides a concise list of analysts' upgrades and downgrades. Click here to register now.